Watch ADPT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
30
FLAG · insiders 26, shorts 34
Insiders, 90 days
−$998K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.9BP/E —DIV YIELD —FCF YIELD -0.62%REV TTM $308.1M +50.1%NET INCOME −$63.9MNET CASH $169.9M52W 12.41 – 26.44NEXT EARNINGS Nov 4 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $71.6M | +21.5% | 71.8% | −$15.8M | −$39.8M | — | -0.25 | −$6.4M | $1.2M | −$7.6M | Aug 4 |
| Q1 2026 · Mar 31 | $70.9M | +35.1% | 73.6% | −$19.2M | −$20M | — | -0.13 | −$9.5M | $796K | −$10.3M | May 5 |
| Q4 2025 · Dec 31derived | $71.7M | +51.0% | 74.6% | −$12.8M | −$13.6M | — | -0.09 | $2.1M | $636K | $1.4M | Feb 26 |
| Q3 2025 · Sep 30 | $94M | +102.4% | 80.7% | $10.3M | $9.5M | — | 0.06 | −$7.1M | $409K | −$7.5M | Nov 5 |
| Q2 2025 · Jun 30 | $58.9M | +36.3% | 69.4% | −$25M | −$25.6M | — | -0.17 | −$12.4M | $655K | −$13.1M | Aug 4 |
| Q1 2025 · Mar 31 | $52.4M | +25.2% | 67.6% | −$29.6M | −$29.9M | — | -0.20 | −$28.5M | $1.3M | −$29.7M | May 5 |
| Q4 2024 · Dec 31derived | $47.5M | +3.7% | 62.0% | −$33.8M | −$33.7M | — | -0.22 | −$12.5M | $80K | −$12.6M | Feb 26 |
| Q3 2024 · Sep 30 | $46.4M | +22.5% | 64.1% | −$32.6M | −$32.1M | — | -0.22 | −$27.1M | $344K | −$27.4M | Nov 5 |
| Q2 2024 · Jun 30 | $43.2M | — | 55.3% | −$47.3M | −$46.2M | — | -0.31 | −$17.3M | $1.7M | −$19M | Aug 5 |
| Q1 2024 · Mar 31 | $41.9M | — | 56.9% | −$48.8M | −$47.5M | — | -0.33 | −$38.4M | $1.5M | −$39.9M | May 1 |
| Q4 2023 · Dec 31derived | $45.8M | — | 57.2% | −$71.1M | −$69.4M | — | -0.48 | −$26.9M | $1.3M | −$28.2M | Feb 26 |
| Q3 2023 · Sep 30 | $37.9M | — | 49.0% | −$51M | −$50.3M | — | -0.35 | −$46.7M | $2.8M | −$49.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $277M | 74.2% | −$57.1M | −$59.5M | -21.5% | -0.39 | −$46M | $3M | −$48.9M | — | — |
| FY2024 · to Dec 31 | $179M | 59.7% | −$162.5M | −$159.5M | -89.1% | -1.08 | −$95.2M | $3.7M | −$98.9M | — | — |
| FY2023 · to Dec 31 | $170.3M | 55.6% | −$227M | −$225.3M | -132.3% | -1.56 | −$156.3M | $10.7M | −$167M | — | — |
| FY2022 · to Dec 31 | $185.3M | 68.7% | −$200.2M | −$200.2M | -108.0% | -1.40 | −$183.9M | $16.3M | −$200.3M | — | — |
| FY2021 · to Dec 31 | $154.3M | 68.1% | −$209M | −$207.3M | -134.3% | -1.48 | −$192.7M | $61.7M | −$254.5M | — | — |
| FY2020 · to Dec 31 | $98.4M | 77.1% | −$152.8M | −$146.2M | -148.6% | -1.11 | −$149.7M | $18.8M | −$168.5M | — | — |
Every number comes from Adaptive Biotechnologies Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.